16 analysts have recently provided ratings on Vertex Pharmaceuticals (NASDAQ:VRTX), with an average 12-month price target of $383.0, a high of $415.00, and a low of $347.00. The current average price target represents a 3.42% increase from the previous average of $370.33. Analysts' actions include maintaining, raising, and lowering ratings and price targets, reflecting their views on the company's performance. Vertex Pharmaceuticals is a biotech company with a focus on cystic fibrosis drugs and a diversifying pipeline. Financially, Vertex has a market cap above industry average, a revenue growth rate of 6.39%, a net margin of 41.69%, an ROE of 6.47%, an ROA of 4.92%, and a low debt-to-equity ratio of 0.05.